Flex Pharma (FLKS) Stock Price Down 5.2%  Donna Armstrong | Aug 17th, 2018
Flex Pharma Inc (NASDAQ:FLKS) fell 5.2% during mid-day trading on Wednesday . The company traded as low as $0.58 and last traded at $0.55. 1,100 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 237,051 shares. The stock had previously closed at $0.58.
A number of brokerages have recently issued reports on FLKS. ValuEngine upgraded shares of Flex Pharma from a "strong sell" rating to a "sell" rating in a research note on Wednesday, May 2nd. Zacks Investment Research lowered shares of Flex Pharma from a "buy" rating to a "hold" rating in a research note on Monday, May 7th. HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Flex Pharma in a research note on Thursday, May 3rd. LADENBURG THALM/SH SH lowered shares of Flex Pharma from a "buy" rating to a "neutral" rating and set a $12.00 target price on the stock. in a research note on Wednesday, June 13th. Finally, Jefferies Financial Group lowered shares of Flex Pharma from a "buy" rating to a "hold" rating in a research note on Wednesday, June 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of "Hold" and an average target price of $14.30. Get Flex Pharma alerts:
The company has a market cap of $11.38 million, a PE ratio of -0.27 and a beta of 2.81.
Flex Pharma (NASDAQ:FLKS) last announced its quarterly earnings data on Friday, August 3rd. The biotechnology company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.05). Flex Pharma had a negative net margin of 3,092.50% and a negative return on equity of 137.76%. The business had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.20 million. sell-side analysts expect that Flex Pharma Inc will post -1.28 earnings per share for the current year.
Several large investors have recently made changes to their positions in FLKS. JPMorgan Chase & Co. grew its position in shares of Flex Pharma by 10,889.2% during the 1st quarter. JPMorgan Chase & Co. now owns 37,583 shares of the biotechnology company's stock valued at $188,000 after buying an additional 37,241 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Flex Pharma by 84.3% during the 2nd quarter. Renaissance Technologies LLC now owns 236,958 shares of the biotechnology company's stock valued at $223,000 after buying an additional 108,358 shares during the last quarter. Finally, Millennium Management LLC grew its position in shares of Flex Pharma by 75.9% during the 1st quarter. Millennium Management LLC now owns 60,126 shares of the biotechnology company's stock valued at $301,000 after buying an additional 25,941 shares during the last quarter. 24.66% of the stock is owned by institutional investors and hedge funds.
Flex Pharma Company Profile ( NASDAQ:FLKS )
Flex Pharma, Inc, a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis; and two Phase 2 clinical trials in the United States for the treatment of patients with motor neuron disease in amyotrophic lateral sclerosis. Flex Pharma Flex Pharm